DALLAS HENSON: Open Payments
NPI 1184343808 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,825 in 104 payments from 14 companies in 2025. Trend: 2023 $812 · 2024 $802 · 2025 $1,825
Food & beverage: $1,825
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 19 | $377 |
| Lundbeck LLC | 11 | $203 |
| E.R. Squibb & Sons, L.L.C. | 11 | $189 |
| Teva Pharmaceuticals USA, Inc. | 10 | $179 |
| Vanda Pharmaceuticals Inc. | 10 | $176 |
| Janssen Pharmaceuticals, Inc | 8 | $167 |
| Neurocrine BioSciences, Inc. | 16 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $94 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
Products named: ARISTADA, ABILIFY ASIMTUFII, COBENFY, FANAPT, INGREZZA, AUSTEDO XR, REXULTI, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
